Clinical Trials
92
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (91 trials with phase data)โข Click on a phase to view related trials
A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects
- Conditions
- Healthy Adult Male
- Interventions
- Drug: Adalimumab (BCD-057) 100 mg/mLDrug: Adalimumab (BCD-057) 50 mg/mLDrug: Adalimumab (Humira) 100 mg/mL
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Biocad
- Target Recruit Count
- 444
- Registration Number
- NCT07181694
- Locations
- ๐ท๐บ
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
๐ท๐บLLC "X7 Clinical Research", Saint Petersburg, Russia
๐ท๐บLLC "Research Center Eco-Safety", Saint Petersburg, Russia
Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erthematosus
- Interventions
- Drug: BCD-256
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Biocad
- Target Recruit Count
- 135
- Registration Number
- NCT07136389
- Locations
- ๐ท๐บ
"Multidisciplinary medical center for adults and children โ157", Saint Petersburg, Russian Federation
Study of the Efficacy and Safety of BCD-131 and Mirceraยฎ in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
- Conditions
- AnemiaChronic Kidney DiseaseChronic Kidney Disease Patients on HemodialysisChronic Kidney Disease 5D
- Interventions
- Biological: BCD-131 (pegdarbepoetin beta)Biological: Mircera (methoxypolyethylene glycol-epoetin beta)
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- Biocad
- Target Recruit Count
- 228
- Registration Number
- NCT07119372
- Locations
- ๐ง๐พ
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology, Minsk, Belarus
๐ท๐บB. Braun Avitum Russland Clinics Ltd., Saint Petersburg, Russian Federation
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Biocad
- Target Recruit Count
- 124
- Registration Number
- NCT07108309
- Locations
- ๐ง๐พ
Health Institution "Brest Regional Oncology Center", Brest, Belarus
๐ง๐พ"Gomel Regional Clinical Oncology Dispensary", Gomel, Belarus
๐ง๐พMinsk City Oncology Center, Minsk, Belarus
Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- Biological: anti-TL1A monoclonal antibody, low doseOther: PlaceboBiological: anti-TL1A monoclonal antibody, medium doseBiological: anti-TL1A monoclonal antibody, high dose
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Biocad
- Target Recruit Count
- 198
- Registration Number
- NCT07080034
- Locations
- ๐ท๐บ
LLC Medical Center "ASTRA", Barnaul, Altayskiy Kray, Russia
๐ท๐บRepublican Clinical Hospital named after G.G. Kuvatov, Ufa, Bashkortostan Republic, Russia
๐ท๐บFederal State Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of the Russian Federation, Rostov-on-Don, Rostov Oblast, Russia
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next